Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

197 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2- advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT.
Steger GG, Egle D, Bartsch R, Pfeiler G, Petru E, Greil R, Helfgott R, Marth C, Öhler L, Hubalek M, Lang A, Tinchon C, Haslbauer F, Redl A, Hock K, Hennebelle M, Mraz B, Gnant M. Steger GG, et al. Breast. 2020 Apr;50:64-70. doi: 10.1016/j.breast.2020.01.035. Epub 2020 Jan 31. Breast. 2020. PMID: 32062536 Free PMC article.
Dual inhibition of HER2 in breast cancer treatment.
Gnant M, Steger GG. Gnant M, et al. Among authors: steger gg. Lancet. 2012 Feb 18;379(9816):596-8. doi: 10.1016/S0140-6736(12)60068-3. Epub 2012 Jan 17. Lancet. 2012. PMID: 22257672 No abstract available.
Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSF.
Wenzel C, Bartsch R, Hussian D, Pluschnig U, Altorjai G, Zielinski CC, Lang A, Haid A, Jakesz R, Gnant M, Steger GG. Wenzel C, et al. Among authors: steger gg. Breast Cancer Res Treat. 2007 Jul;104(1):109-14. doi: 10.1007/s10549-006-9397-3. Epub 2006 Oct 24. Breast Cancer Res Treat. 2007. PMID: 17061042 Clinical Trial.
HER-2-positive breast cancer: hope beyond trastuzumab.
Bartsch R, Wenzel C, Zielinski CC, Steger GG. Bartsch R, et al. Among authors: steger gg. BioDrugs. 2007;21(2):69-77. doi: 10.2165/00063030-200721020-00001. BioDrugs. 2007. PMID: 17402790 Review.
The potential risk of neoadjuvant chemotherapy in breast cancer patients--results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07).
Taucher S, Steger GG, Jakesz R, Tausch C, Wette V, Schippinger W, Kwasny W, Reiner G, Greil R, Dubsky P, Poestlberger S, Tschmelitsch J, Samonigg H, Gnant M; Austrian Breast and Colorectal Cancer Study Group-07. Taucher S, et al. Among authors: steger gg. Breast Cancer Res Treat. 2008 Nov;112(2):309-16. doi: 10.1007/s10549-007-9844-9. Epub 2007 Dec 14. Breast Cancer Res Treat. 2008. PMID: 18080748 Clinical Trial.
197 results